In multiple myeloma, investigations targeting the B-cell maturation antigen (BCMA) yielded encouraging outcomes with reversible toxic effects such as cytokine release syndrome (CRS) and pancytopenia13–17. Here, TNFRSF17 is linked to plasma cell myeloma.